| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC25013 | ARM-1 Featured | A novel LTA4 hydrolase (LTA4H) inhibitor that inhibits LTB4 synthesis in human neutrophils with IC50 of 0.5 uM. |
|
| DC22856 | ARN-5187 | A novel lysosomotropic REV-ERB ligand that has a dual inhibitory activity toward REV-ERB-mediated transcriptional regulation and autophagy. |
|
| DC21378 | Piromelatine | A novel melatonin melatonin receptor MT1/MT2 and serotonin 5-HT1A/5-HT1D receptor agonist. |
|
| DC11928 | MPT0B002 | A novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells. |
|
| DC11935 | PBOX-15 | A novel microtubule targeting agent that induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple cancer cells. |
|
| DC22773 | DSR-71167 | A novel mineralocorticoid receptor antagonist (IC50=0.26 uM) with carbonic anhydrase inhibitory activity (IC50=19 uM). |
|
| DC11929 | ME-344 | A novel mitochondrial and mTOR inhibitor with potent anti-cancer activity, inhibits leukemia cell lines with IC50 of 70-260 nM. |
|
| DC11775 | DS44170716 | A novel MPT (mitochondrial permeability transition) inhibitor of that inhibits Ca2+-induced MPT in rat liver isolated mitochondria. |
|
| DC22955 | LUF7244 | A novel negative allosteric modulator of dofetilide binding to the Kv11.1 (hERG) channel with the strongest effect at 10 uM (IC50=3.9 uM). |
|
| DC10801 | AMPA/kainate antagonist-1 Featured | A novel Non-competitive AMPA/kainate antagonist. |
|
| DC10808 | AMPA/kainate antagonist-3 Featured | A novel Non-competitive AMPA/kainate antagonist. |
|
| DC10802 | AMPA/kainate antagonist-2 | A novel Non-competitive AMPA/kainate antagonist. |
|
| DC20293 | 14-3-3 inhibitor BV2 | A novel nonpeptidic inhibitor of 14-3-3 protein-protein interaction that promotes the apoptotic death of cells expressing either wt Bcr-Abl construct or T315I mutation. |
|
| DC11930 | EDD3 | A novel Notch inhibitor that reduces protein expression of NOTCH1, NICD and HES1 in HEK293 cells and downregulates Notch target genes. |
|
| DC11910 | IPL-576092 | A novel orally active, anti-inflammatory compound that inhibits leukocyte infiltration and changes in lung function in response to allergen challenge. |
|
| DC23994 | Peretinoin | A novel orally available, synthetic retinoid with potential antineoplastic and chemopreventive activities. |
|
| DC11811 | SCY-078 | A novel orally bioavailable fungal beta-1,3-D glucan synthetase inhibitor against Candida species C. glabrata (MIC 0.03 to 0.25 ug/ml), C. parapsilosis (MIC 0.06 to 0.25 ug/ml). |
|
| DC24203 | P2X2/3 receptor antagonist Featured | A novel P2X3 and P2X2/3 receptor antagonist useful for the treatment of urinary tract diseases, pain, respiratory diseases and cardiovascular diseases. |
|
| DC22434 | POL5551 | A novel peptidic, potent and highly selective CXCR4 antagonist with IC50 of 1.7 nM. |
|
| DC3161 | Prasugrel Featured | A novel platelet inhibitor |
|
| DC23635 | YM 758 | A novel potent "funny" If current channel (If channel) inhibitor that inhibits rOct1- and hOCT1-mediated [3H]MPP uptake with IC50 of 23.8 and 40.5 uM, respectively. |
|
| DC23542 | LY3031207 | A novel potent (IC50=910 ng/mL), highly selective microsomal prostaglandin E synthase 1 inhibitor (mPGES-1) for treatment of undisclosed indications.. |
|
| DC11994 | ZQ-16 | A novel potent and selective agonist of GPR84 that induces calcium response with EC50 of 0.213 uM. |
|
| DC23841 | EW-7195 Featured | A novel potent and selective TGF-βRI (ALK5) inhibitor with IC50 of 4.83 nM, dispalys >300-fold selectivity over p38α. |
|
| DC22734 | UR-1102 | A novel potent and selective, orally active URAT1 inhibitor with Ki of 57 nM, 130 and 42-fold selectivity over OAT1 and OAT3, respectively. |
|
| DC20826 | BPR1K653 hydrochloride | A novel potent Aurora kinase inhibitor that inhibits Aurora-A and Aurora-B with IC50 of 24 nM and 45 nM, respectively. |
|
| DC21048 | GIV3727 | A novel potent bitter receptor (TAS2Rs) antagonist that inhibits activation of hTAS2R31 by saccharin and acesulfame K with IC50 of 6.4 and 7.9 uM respectively. |
|
| DC20534 | Revosimeline | A novel potent cannabinoid receptor agonist.. |
|
| DC20435 | Leucettine L41 | A novel potent cdc2-like kinase (CLKs) and DYRKs inhibitor with IC50 of 40, 35 and 15 nM for DYRK1A, DYRK2 and CLK1, respectively. |
|
| DC21453 | Riviciclib | A novel potent CDK inhibitor with IC50 of 79 nM, 63 nM and 20 nM for Cdk4/cyclin D1, Cdk1/cyclin B and Cdk9/cyclin T1, respectively. |
|
